These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24048905)

  • 21. Biological agents in management of osteoporosis.
    Tella SH; Gallagher JC
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Assessment of bone quality. Drug developments for restoring bone mass and quality in the treatment of osteoporosis].
    Nakamura T
    Clin Calcium; 2008 Mar; 18(3):374-80. PubMed ID: 18310826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Teriparatide (rhPTH 1-34) for the treatment of osteoporosis.
    Ebeling PR; Russell RG
    Int J Clin Pract; 2003 Oct; 57(8):710-8. PubMed ID: 14627183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Denosumab for postmenopausal osteoporosis?
    Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Teriparatide--new value in osteoporosis treatment: treatment guidelines].
    Korsić M; Kastelan D
    Reumatizam; 2006; 53(2):77-81. PubMed ID: 17580560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coming to grips with bone loss.
    Marx J
    Science; 2004 Sep; 305(5689):1420-2. PubMed ID: 15353792
    [No Abstract]   [Full Text] [Related]  

  • 30. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
    Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
    J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis.
    Lyritis GP; Georgoulas T; Zafeiris CP
    Ann N Y Acad Sci; 2010 Sep; 1205():277-83. PubMed ID: 20840284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
    Krege JH; Wan X
    Bone; 2012 Jan; 50(1):161-4. PubMed ID: 22036910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibodies for the treatment of osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2013 Feb; 13(2):183-96. PubMed ID: 23253281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Osteoporosis and oral biology].
    Ikeo T; Kamada A; Goda S
    Clin Calcium; 2007 Feb; 17(2):150-6. PubMed ID: 17272870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
    Lewiecki EM
    IDrugs; 2009 Dec; 12(12):799-809. PubMed ID: 19943223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biological therapy for osteoporosis].
    Nakamura S; Tanaka S
    Clin Calcium; 2014 Jun; 24(6):919-25. PubMed ID: 24870844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.